In connection with the previously announced transaction with Mayne Pharma, TherapeuticsMD has significantly reduced its operating expenses. The termination of certain members of the Company's executive management team and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full during the first quarter of 2023, and severance obligations for terminated executive officers will be paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2022, the Company employed one full-time employee primarily engaged in an executive position. The Company engaged external consultants, including certain former members of its management team, to support TXMD's relationship with current partners and assist with certain financial, legal, and regulatory matters, and the continued wind-down of historical business operations.